Argen X SE - ADR

NASDAQ:ARGX   3:59:59 PM EDT
279.34
-2.51 (-0.89%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)14.23B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$14.51 Million
Adjusted EPS-$4.41
See more estimates
10-Day MA$289.20
50-Day MA$312.67
200-Day MA$305.27
See more pivots

Argen X SE - ADR Stock, NASDAQ:ARGX

Willemstraat 5, Breda, Noord-Brabant 4811 AH
Netherlands
Phone: +31.76.303.04.88
Number of Employees: 336

Description

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.